Search Result

Results for "

tumor microenvironment

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (1) ADC Linker (1) Adenosine Receptor (1) Akt (4) Apoptosis (14) Autophagy (3) Bcl-2 Family (1) BMI1 (2) c-Fms (2) CCR (3) CD47 (1) CD73 (1) Checkpoint Kinase (Chk) (1) Complement System (1) COX (4) CTLA-4 (1) CXCR (1) DNA Methyltransferase (1) Drug-Linker Conjugates for ADC (2) Elastase (1) Endogenous Metabolite (5) ERK (1) Fluorescent Dye (1) HDAC (1) HSP (1) Indoleamine 2,3-Dioxygenase (IDO) (3) Integrin (2) Interleukin Related (1) Isotope-Labeled Compounds (1) Ligands for E3 Ligase (1) MEK (1) METTL3 (1) Microtubule/Tubulin (1) MMP (1) Molecular Glues (1) mTOR (3) NF-κB (1) NKCC (1) Parasite (6) PARP (1) PD-1/PD-L1 (4) PDGFR (1) PDHK (1) PI3K (2) PKD (1) Protein Arginine Deiminase (2) Raf (1) Ras (2) Reactive Oxygen Species (4) STAT (1) STING (2) TGF-β Receptor (1) Tie (1) Toll-like Receptor (TLR) (4) VEGFR (1)
By Research Areas:	Cancer (65) Endocrinology (1) Infection (6) Inflammation/Immunology (15) Metabolic Disease (6) Neurological Disease (3)
Click Chemistry:	Azide (1)
Oligonucleotides:	Aptamers (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990042

Gotistobart ONC-392; BNT 316	CTLA-4	Cancer
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .

HY-131347

PD-1/PD-L1-IN-NP19	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC₅₀ of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects .

HY-160421

TREM2-IN-1	Apoptosis	Inflammation/Immunology Cancer
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 ⁺ and CX₃CR1 ⁺ immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells .

HY-139245

MC-Ala-Ala-Asn-PAB	ADC Linker	Cancer
MC-Ala-Ala-Asn-PAB is a linker extracted from patent CN104147612A, page 14. MC-Ala-Ala-Asn-PAB can be used to synthesis the tumor microenvironment specific activated micromolecular targeted conjugate .

HY-154850

F-CRI1	STING	Cancer
F-CRI1 is a potent STING agonist with a K_d value of 40.62 nM. F-CRI1 is a radioactive probe with 18F-labeled modification. F-CRI1 can be used to study STING visualization in the tumor microenvironment .

HY-151559

Zn-DPA-maytansinoid conjugate 1	Checkpoint Kinase (Chk) STAT CXCR CCR	Cancer
Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. Zn-DPA-maytansinoid conjugate 1 induces lasting regression of tumor growth and rejuvenates tumor microenvironment (TME) to an "inflamed hot tumor" .

HY-168088

DNMT1/HDAC-IN-1	HDAC DNA Methyltransferase	Cancer
DNMT1/HDAC-IN-1 (compound (R)-23a) is a DNMT1/HDAC dual inhibitor (HDAC1:IC₅₀=0.05 μM), HDAC1 is a major HDAC isoform that interacts with DNMT1 in multiple protein complexes for transcriptional silencing of TSGs. DNMT1/HDAC-IN-1 can reshape the tumor immune microenvironment and induce tumor regression, and effectively reverse cancer-specific epigenetic abnormalities .

HY-154869

PD-1/PD-L1-IN-34	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits PD-1/PD-L1 interaction (IC₅₀=0.029 μM), with a selected binding affinity with PD-L1 (K_D=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment .

HY-164529

SJ-C1044	Raf Ras MEK ERK VEGFR Tie c-Fms	Cancer
SJ-C1044 is an orally available pan-RAF inhibitor with immunomodulatory and anti-tumor activities. SJ-C1044 inhibits wild-type BRAF, wild-type CRAF, and BRAF (V600E) with IC₅₀ values ??of 331, 257, and 187 nM, respectively. SJ-C1044 inhibits tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. In addition, SJ-C1044 also has a certain inhibitory effect on VEGFR2, TIE2, and CSF1R, with IC₅₀ values ??of 100, 23, and 235 nM, respectively. SJ-C1044 improves the tumor immune microenvironment by inhibiting angiogenesis and regulating macrophage function. SJ-C1044 can be used in the study of colorectal cancer .

HY-157157

PAD4-IN-3	Protein Arginine Deiminase	Cancer
PAD4-IN-3 (compound 4B) is a PAD4 inhibitor with antitumor activity in vitro and in vivo. PAD4-IN-3 was covalently linked to RGD sequence peptide-modified chitosan (K-CRGDV), resulting in an enhanced oxidative stress-responsive nanoagent. K-CRGDV-PAD4-IN-3 can actively target tumors, inhibit PAD4 activity, block the formation of neutrophil extracellular traps (NETs), and improve the tumor immune microenvironment in response to the tumor microenvironment .

HY-P10388

TAX2 peptide	CD47 TGF-β Receptor	Cancer
TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment .

HY-135748

Polyinosinic-polycytidylic acid sodium Maximum Cited Publications 19 Publications Verification Poly(I:C) sodium	Toll-like Receptor (TLR) Apoptosis	Inflammation/Immunology Cancer
Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis .

HY-134958

Polyinosinic-polycytidylic acid potassium Poly(I:C) potassium	Toll-like Receptor (TLR) Apoptosis	Inflammation/Immunology Cancer
Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid potassium can directly trigger cancer cells to undergoApoptosis .

HY-160053

Gint4.T aptamer sodium	PDGFR	Cancer
Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .

HY-148494

Tivumecirnon FLX475	CCR	Inflammation/Immunology Cancer
Tivumecirnon (FLX475) is an orally bioactive, selective CCR4 antagonist. Tivumecirnon can block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment, leading to enhanced antitumor activity. Tivumecirnon has antitumor activity on EBV+ NK/T cell lymphoma and non-small cell lung cancer (NSCLC) combined with Pembrolizumab (HY-P9902). Tivumecirnon is promising for research of broad range of tumor types .

HY-146215

IDO1-IN-20	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
Hy-146215 is an enzyme that catalyzes the oxidative metabolism of tryptophan. It can immunosuppress tumors in the tumor microenvironment.

HY-116604

RLX PD 139530	Others	Cancer
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness. RLX highlights the necessity for further research into the tumor microenvironment’s dynamics to develop more tailored treatment approaches for diverse tumor types.

HY-161248

E7130	Microtubule/Tubulin	Cancer
E7130 is a microtubule inhibitor, which ameliorates the tumor microenvironment through suppression of cancer-associated fibroblasts (CAF) and promotion of tumor vasculature remodeling .

HY-163642

TNF-α agonistic 1	Others	Cancer
TNF-α agonistic 1 (compound 22a) can repolarize tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) from the M2 phenotype to the M1 anti-tumor phenotype .

HY-159127

HRS-4642	Ras	Cancer
HRS-4642 is a selective KRAS(G12D) inhibitor (Kd=0.083 nM) with anti-cancer activity. HRS-4642 synergizes with Carfilzomib (HY-10455) and exhibits significant in vivo potency to reshape the tumor microenvironment into an immune-activating microenvironment.

HY-116071

Autophagy-IN-3	Autophagy	Cancer
Autophagy-IN-3 (Compound 6k) is an autophagy inhibitor. Autophagy-IN-3 promotes metabolic stress in the tumor microenvironment and enhances the effects of cytostatics in combined treatments .

HY-P3448

Certepetide CEND-1; iRGD; LSTA1	Integrin Complement System	Cancer
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .

HY-163146

TME-HYM (PH Probe)	Fluorescent Dye	Cancer
TME-HYM (PH Probe) is a novel fluorescent probe based on acidic tumor microenvironment (TME) activation and organic anion transporting polypeptide (OATPs, overexpressed on cancer cells), and can be selective uptaken. TME-HYM (PH Probe) can selectively lit up cancer cells and tumor tissues, offering dual tumor selectivity for precise visualization of tumor mass .

HY-164502

NAP1051	Akt	Cancer
NAP1051 is a biomimetic analog of lipin A4 that achieves anti-tumor effects by targeting the inflammatory tumor microenvironment. NAP1051 inhibits neutrophil chemotaxis to fMLP and stimulates macrophage efferocytosis by activating AKT. NAP1051 can be used in colorectal cancer research .

HY-P99742

Mitazalimab ADC-1013; JNJ-64457107	TNF Receptor	Cancer
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .

HY-147204

Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE (compound S6) is a potent anticancer agent, which can be specific activated by tumor microenvironment. Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE can suppress tumor growth in mice (extracted from patent CN104147612A) .

HY-P99039

Oleclumab MEDI9447	CD73	Cancer
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .

HY-137206

ALV2	Ligands for E3 Ligase Molecular Glues	Cancer
ALV2 is a potent and selective Helios degrader. ALV2 binds CRBN, with an IC₅₀ of 0.57 μM. Helios is the zinc-finger transcription factor that can maintain a stable T_reg cell phenotype in the inflammatory tumor microenvironment .

HY-16938

5'-Methylthioadenosine 3 Publications Verification 5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine	Endogenous Metabolite Apoptosis Parasite	Metabolic Disease Cancer
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis . 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis .

HY-130117

AlbA-DCA	Reactive Oxygen Species Apoptosis	Cancer
AlbA-DCA is a conjugate formed by the attachment of Albiziabioside A (AlbA) to a dichloroacetate acid (DCA) subunit. AlbA-DCA can induce a marked increase in intracellular ROS and alleviate the accumulation of lactic acid in tumor microenvironment (TME), and also selectively kills cancer cells and induce apoptosis .

HY-156677

STC-15	METTL3	Cancer
STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .

HY-Y0445A

Sodium dichloroacetate 15+ Cited Publications	PDHK Reactive Oxygen Species NKCC Apoptosis	Cancer
Sodium dichloroacetate is a metabolic regulator in cancer cells' mitochondria with anticancer activity. Sodium dichloroacetate inhibits PDHK, resulting in decreased lactic acid in the tumor microenvironment. Sodium dichloroacetate increases reactive oxygen species (ROS) generation and promotes cancer cell apoptosis. Sodium dichloroacetate also works as NKCC inhibitor .

HY-163081

PARP7-IN-17	PARP	Cancer
PARP7-IN-17 is a potent inhibitor of PARP7 with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

HY-15888

PTC-209 5+ Cited Publications	BMI1 Autophagy	Cancer
PTC-209 is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment .

HY-16938S

5'-Methylthioadenosine-13C6 5'-(Methylthio)-5'-deoxyadenosine-¹³C₆; 5'-Deoxy-5'-(methylthio)adenosine-¹³C₆; 5'-S-Methyl-5'-thioadenosine-¹³C₆	Endogenous Metabolite Apoptosis	Metabolic Disease Cancer
5'-Methylthioadenosine- ¹³C₆ is the ¹³C-labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].

HY-128946

CL2A-SN-38 2 Publications Verification	Drug-Linker Conjugates for ADC	Inflammation/Immunology Cancer
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects .

HY-16938S1

5'-Methylthioadenosine-d3 5'-(Methylthio)-5'-deoxyadenosine-d₃; 5'-Deoxy-5'-(methylthio)adenosine-d₃; 5'-S-Methyl-5'-thioadenosine-d₃	Apoptosis Parasite Endogenous Metabolite	Inflammation/Immunology
5'-Methylthioadenosine-d₃ is the deuterium labeled 5'-Methylthioadenosine[1]. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2][3][4].

HY-15888A

PTC-209 hydrobromide 5+ Cited Publications	BMI1 Autophagy	Cancer
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment .

HY-164429

VIP236	Integrin Elastase	Cancer
VIP236 is a small-molecule-drug conjugates (SMDCs) consisting of an αvβ3 integrin binder linked to an optimized Camptothecin (HY-16560) topoisomerase I (TOP1) inhibitor payload. VIP236 exerts anticancer activity by targeting αvβ3 integrins, and it can release payload upon cleavage by neutrophil elastase in the tumor microenvironment .

HY-125836

CCR4 antagonist 2	CCR	Endocrinology Cancer
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits T_reg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC₅₀ values of Ca ²⁺flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-144274

IDO1-IN-14	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IDO1-IN-14 (compound 4a) is a potent IDO1 inhibitor with an IC₅₀ of 396.9 nM. IDO1-IN-14 has cellular IDO1 inhibition (HeLa EC₅₀=3393 nM) .

HY-144273

IDO1-IN-13	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IDO1-IN-13 (compound 27a) is a potent IDO1 inhibitor with an IC₅₀ of 61.6 nM. IDO1-IN-13 has cellular IDO1 inhibition (HeLa EC₅₀= 30 nM). IDO1-IN-13 decreases 51% of the kyn/trp ratio in SK-OV-3 xenograft tumor tissues .

HY-158057

A2AR/A2BR antagonist 1	Adenosine Receptor	Cancer
A_2AR/A_2BR antagonist 1 (compound 7ai) has a dual antagonistic effect on A_2AR/A_2BR, with the IC₅₀ values of 11.2 nM and 6.4 nM for A_2AR and A_2BR, respectively. A_2AR/A_2BR antagonist 1 promotes T cell-mediated cancer cell death .

HY-107202

Polyinosinic-polycytidylic acid Maximum Cited Publications 19 Publications Verification Poly(I:C)	Toll-like Receptor (TLR) PKD HSP Bcl-2 Family Interleukin Related	Infection Inflammation/Immunology Cancer
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis .

HY-159577

Nic-15	PI3K mTOR Akt	Cancer
Nic-15 (compound 4n) is an anti-constrictive agent used to antagonize the hypovascularity of pancreatic tumors. The hypovascularity allows cancer cells to adapt to the nutrient-deficient tumor microenvironment and develop drug resistance. Nic-15 can regulate the PI3K/Akt/mTOR pathway and alleviate ER stress induced by Gemcitabine (HY-17026). Nic-15 can significantly inhibit the migration and colony formation of MIA PaCa-2 and PANC-1 pancreatic cancer cells. The combination of Nic-15 and Gemcitabine can effectively solve the problem of pancreatic tumor resistance. In an in vivo xenograft model, Nic-15 can significantly enhance the efficacy of Gemcitabine .

HY-162494

PAD4-IN-4	Protein Arginine Deiminase	Cancer
PAD4-IN-4 (compound 28) is a potent PAD4 inhibitor (IC₅₀=0.79±0.09 μM). PAD4-IN-4 improves the tumor immune microenvironment by reshaping neutrophil phenotype, upregulating the proportions of dendritic cells and M1 macrophages, and reducing the amount of myeloid-derived suppressor cells. PAD4-IN-4 can be used for Triple-negative breast cancer research .

HY-B0722

Histamine dihydrochloride 5+ Cited Publications	Endogenous Metabolite Reactive Oxygen Species	Metabolic Disease Cancer
Histamine dihydrochloride is a reactive oxygen species (ROS) inhibitor. Histamine dihydrochloride can suppress ROS production and work together with IL-2 to activate T cells and NK cells, leading to immune activation in the tumor microenvironment, which consequently kills acute myeloid leukemia (AML) cells. Histamine dihydrochloride can cause a reduction in vaginal tetrazo reduction, increased epithelial growth, and heightened keratinization in mouse models of ovariectomy. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-144746

PD-1/PD-L1-IN-26	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of PD-1/PD-L1 with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases .

HY-N3387

Licoricidin	Apoptosis NF-κB Akt MMP	Inflammation/Immunology Cancer
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC₅₀=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .

Cat. No.	Product Name

HY-L025

Anti-Cancer Compound Library

8,055 compounds

Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.

MCE designs a unique collection of 8,055 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

HY-L204

Lactic Acid Metabolic Compound Library

326 compounds

Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism.

MCE contains 326 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.

Cat. No.	Product Name	Target	Research Area

HY-P4116

pH-Low Insertion Peptide pHLIP	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors .

HY-P4116A

pH-Low Insertion Peptide TFA pHLIP TFA	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors .

HY-P3448

Certepetide CEND-1; iRGD; LSTA1	Integrin Complement System	Cancer
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .

HY-P10388

TAX2 peptide	CD47 TGF-β Receptor	Cancer
TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment .

HY-P10449

M2 Peptide	Peptides	Cancer
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .

Cat. No.	Product Name	Target	Research Area

HY-P990042

Gotistobart ONC-392; BNT 316	CTLA-4	Cancer
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .

HY-P99046

Selicrelumab	Inhibitory Antibodies	Cancer
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study .

HY-P99742

Mitazalimab ADC-1013; JNJ-64457107	TNF Receptor	Cancer
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .

HY-P99039

Oleclumab MEDI9447	CD73	Cancer
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16938

5'-Methylthioadenosine 3 Publications Verification 5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Apoptosis Parasite
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis . 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis .

HY-B0722

Histamine dihydrochloride 5+ Cited Publications	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Reactive Oxygen Species
Histamine dihydrochloride is a reactive oxygen species (ROS) inhibitor. Histamine dihydrochloride can suppress ROS production and work together with IL-2 to activate T cells and NK cells, leading to immune activation in the tumor microenvironment, which consequently kills acute myeloid leukemia (AML) cells. Histamine dihydrochloride can cause a reduction in vaginal tetrazo reduction, increased epithelial growth, and heightened keratinization in mouse models of ovariectomy. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-N3387

Licoricidin	Structural Classification Natural Products Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Plants Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields	Apoptosis NF-κB Akt MMP
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC₅₀=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .

HY-B0722R

Histamine dihydrochloride (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Endogenous Metabolite Reactive Oxygen Species
Histamine (dihydrochloride) (Standard) is the analytical standard of Histamine (dihydrochloride). This product is intended for research and analytical applications. Histamine dihydrochloride is a reactive oxygen species (ROS) inhibitor. Histamine dihydrochloride can suppress ROS production and work together with IL-2 to activate T cells and NK cells, leading to immune activation in the tumor microenvironment, which consequently kills acute myeloid leukemia (AML) cells. Histamine dihydrochloride can cause a reduction in vaginal tetrazo reduction, increased epithelial growth, and heightened keratinization in mouse models of ovariectomy. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

Cat. No.	Product Name	Chemical Structure

HY-16938S

5'-Methylthioadenosine-13C6

5'-Methylthioadenosine- ¹³C₆ is the ¹³C-labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].

HY-16938S1

5'-Methylthioadenosine-d3

5'-Methylthioadenosine-d₃ is the deuterium labeled 5'-Methylthioadenosine[1]. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2][3][4].

HY-78131S3

Ibuprofen-13C6

Ibuprofen- ¹³C₆ ((±)-Ibuprofen- ¹³C₆) is a ¹³C labeled Ibuprofen (HY-78131). Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .

Cat. No.	Product Name		Classification

HY-159129

hCAXII-IN-10		Azide
hCAXII-IN-10 (Compound 18b) is a dual inhibitor of human carbonic anhydrase isoform XII (hCAXII) and cathepsin B, with a K_i value of 2.2 nM. hCAXII-IN-10 can inhibit the role of hCAXII in providing tumors with a pH microenvironment conducive to tumor growth, and is expected to be used in the study of tumor diseases .

Cat. No.	Product Name		Classification